Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis

Journal of Hepatology

Volumn 24, Issue 2, 1996, Pages 141-147

  Mazzella, Giuseppe ^a   Accogli, Esterita ^a   Sottili, Sandra ^a   Festi, Davide ^b   Orsini, Monica ^a   Salzetta, Antonio ^a   Novelli, Vieri ^a   Cipolla, Antonio ^a   Fabbri, Carlo ^a   Pezzoli, Alessandro ^a   Roda, Enrico ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alpha interferon; Cirrhosis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0030020455     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80022-5     Document Type: Article

References (46)

1. Smuzness W. Hepatocellular carcinoma and hepatitis B virus: evidence for a causal association. Prog Med Virol 1978; 24: 40-69.
2. Popper H. The relation between hepatitis B virus infection and hepatocellular carcinoma. Hepatogastroenterology 1986; 33: 2-5.
3. Beasley RP. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
4. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B related sequelae. Prospective study in 1400 hepatitis B surface antigen positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-4.
5. Resnik RH, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 1983; 28: 908-11.
6. Gilliam JH III, Geisinger KR, Richter JE. Primary hepatocellular carcinoma after chronic non-A, non-B, posttransfusion hepatitis. Ann Intern Med 1984; 101: 794-5.
7. Colombo M, Choo Q L, Del Ninno E, Dioguardi N, Kuo G, Donato MF, Tommasini MA, Houghton M. Prevalence of antibody to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
8. Simonetti RG, Cammà C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 2: 97-102.
9. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case controlled study. Cancer 1992; 69: 2052-4.
10. Ruiz J, Sangro B, Cuende JI, Beloqui O, Riezu-Boj J, Herrero JI, Prieto J. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992; 16: 637-41.
11. Yoffe B, Noonan C. Hepatitis B virus. New and evolving issues. Dig Dis Sci 1992; 37: 1-9.
12. Alberti A, Pontisso P. Hepatitis viruses as aetiological agents of hepatocellular carcinoma. Ital J Gastroenterol 1991; 23: 452-6.
13. Villa E, Baldini GM, Pasquinelli C, Melegari M, Cariani E, Di Chirico G, Manenti F. Risk factors for hepatocellular carcinoma in Italy: male sex, hepatitis B virus, non-A, non-B infection and alcohol. Cancer 1988; 62: 611-5.
14. Caporaso N, Romano M, Marmo R, de Sio I, Morisco F, Minerva A, Coltorti M. Hepatitis C virus is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1991; 12: 367-71.
15. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenetic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian Study. Hepatology 1994; 20: 1225-30.
16. La Vecchia C, Negri E, Decarli A, D'Avanzo C, Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer 1988; 42: 872-6.
17. Filippazzo MG, Aragona E, Cottone M, Dardanoni G, Ianzarone F, Marenghini A, Patti C, Sciarrino E, Simonetti R, Tinè F, Pagliaro L. Assessment of some risk factors for hepatocellular carcinoma: a case control study. Stat Med 1985; 4: 345-51.
18. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kimatura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
19. Hirayama T. A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking. Cancer Chemother Pharmacol 1989; 23: Suppl: S114-7.
20. Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317: 940-5.
21. Strander H, Öberg K. Clinical use of interferons: solid tumors. In: Baron S, Coppenhaver DH, Dianzani F, et al. eds. Interferon, Principles and Medical Applications 1st. Edn. The University of Texas Medical Branch at Galveston: 1992; 533-61.
22. Colleoni M, Buzzoni R, Bajetta E, Bochicchio AM, Bartoli C, Audisio R, Bonfanti G, Nolè F. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993; 72: 3196-201.
23. Kardinal CG, Moertel CG, Wieand HS, Schutt AJ, O'Connel MJ, Wright K, Wiesenfeld M, Tschetter LK, Krook JE. Combined doxorubicin and alpha interferon therapy of advanced hepatocellular carcinoma. Cancer 1993; 71: 2187-90.
24. Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schoub BD, Kew MC. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer 1985; 52: 105-9.
25. Oon CG. Long term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31: S137-42.
26. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972; 34: 187-220.
27. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
28. Benedetti J, Yuen K, Young L. Life tables and survival functions. In: Dixon WJ, ed. BMDP Statistical Software. Berkeley: University of California Press, 1983: 557-75.
29. Villa E, Melegari M, Scaglioni PP, Trande P, Cesaro P, Manenti F. Hepatocellular carcinoma: risk factors other than HBV. Ital J Gastroenterol 1991; 23: 457-60.
30. Lok AS, Weller IV, Karayannis P, Brown D, Fowler MJF, Monjardino J, Thomas HC, Sherlock S. Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver 1984; 4: 45-9.
31. Barbara L, Mazzella G, Baraldini M, Gasbarrini G, Giungi F, Malavolti M, Mastroroberto L, Miglio F, Roda E, Raisa E, Rizzetto M, Saracco G. A randomized controlled trial with human lymphoblastoid interferon vs no treatment in chronic hepatitis B virus infection. Preliminary results. J Hepatol 1986; 3: S235-8.
32. Saracco G, Mazella G, Rosina F, Cancellieri C, Lattore V, Raise E, Rocca G, Giorda L, Verme G, Gasbarrini G, Barbara L, Bonino F, Rizzetto M, Roda E. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 336-41.
33. Hoofnagle JH, Peters M, Mullen KD, Jones D B, Rustgy V, Di Bisceglie A, Hallahan C, Park Y, Hallahan C, Park Y, Jones EA. Randomized, controlled trial of recombinant human α-Interferon in patients with chronic hepatitis B. Gastroenterology 1989; 95: 318-25.
34. Hoofnagle JH, Mullen KD, Jones DB, Rustgy V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
35. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Leffkowitch J, Albrecht J, Meschievitz C, Ortego TG, Gibas A, Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter, randomized, controlled trial. N Engl J Med 1989; 321: 1501-6.
36. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis. A multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7.
37. Tińe F, Magrin S, Craxì A, Pagliaro L. Alpha interferon in non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 1992; 13: 192-9.
38. Mazella G, Salzetta A, Casanova S, Morelli MC, Villanova N, Miniero R, Sottili S, Novelli V, Cipolla A, Festi D, Roda E. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response. Dig Dis Sci 1994; 39: 866-70.
39. Korenman J, Baker B, Waggoner J, Everhardt JE, Di Bisceglie AM, Hoofnagle JH. Long term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 628-34.
40. Lok ASF, Chung HT, Liu VWS, Ma OCK. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993: 105: 1833-8.
41. Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15: 102-6.
42. Saracco G, Rosina F, Abate ML, Carucci P, Solinas A, Chiandussi L, Bonino F, Verme G, Rizzetto M. Long-term response to interferon-alfa 2b retreatment in chronic hepatitis C. J Hepatol 1994; 21: 278-9.
43. Colombo M. De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
44. Hino O, Shows T, Rogler CE. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17,18 translocation. Proc Natl Acad Sci USA 1986; 83: 8338-42.
45. Zhou YZ, Slagle BL, Donehover LA, VanTuinen P, Ledbetter DH, Butel JS. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J Virol 1988; 62: 4224-31.
46. Fourel G, Trepo C, Bougueleret L. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumors. Nature 1990; 347: 294-8.